Despite the limitation of our model in which this synergistic effect required overexpression of MEF2C, these results point to the potential of SIK inhibitors in combination with steroid treatment for patients with ETP-ALL, who generally are more resilient toward steroid treatment. This evidence concerns the gene MEF2C and acute lymphoblastic leukemia.